Background/aim: New treatment regimens for COVID-19, which has threatened the world recently, continue to be investigated. Although some of the treatments are promising, it is thought to be early to state that there is definitive treatment. Experiences and treatment protocol studies from treatment centers are still important. The aim of this study is to evaluate factors affecting the treatment process of the first cases followed in our clinic. Materials and methods: The consecutive hospitalized patients with COVID-19 pneumonia were analyzed in this retrospective and cross-sectional study. Data were recorded from the electronic and written files of patients. Results: Eighty-three patients were evaluated. The median age was 50 ± 15 years. Forty-eight (57.8%) patients had one or more comorbidities. The most common comorbidity was hypertension. The most common symptom was cough in 58 patients (70%). The overall mortality was 15%, and 85% of the patients were discharged. The time between the onset of symptoms and hospitalization was statistically significantly longer in deceased patients (P = 0.039). Age, D-Dimer, troponin, CK, CK-MB, ferritin, procalcitonin, and neutrophil to lymphocyte ratio were statistically significantly higher in deceased patients than survivor patients. In subgroup analysis, in the patients receiving azithromycin plus hydroxychloroquine and other antibiotics plus hydroxychloroquine, the duration of hospitalization was shorter in the azithromycin group (P = 0.027). Conclusion: Early treatment and early admission to the hospital can be crucial for the better treatment process. Combination therapy with azithromycin may be preferred in the first treatment choice because it can shorten the length of hospital stay. This work is licensed under a Creative Commons Attribution 4.0 International License.
Background/aim: New treatment regimens for COVID-19, which has threatened the world recently, continue to be investigated. Although some of the treatments are promising, it is thought to be early to state that there is definitive treatment. Experiences and treatment protocol studies from treatment centers are still important. The aim of this study is to evaluate factors affecting the treatment process of the first cases followed in our clinic. Materials and methods: The consecutive hospitalized patients with COVID-19 pneumonia were analyzed in this retrospective and cross-sectional study. Data were recorded from the electronic and written files of patients. Results: Eighty-three patients were evaluated. The median age was 50 ± 15 years. Forty-eight (57.8%) patients had one or more comorbidities. The most common comorbidity was hypertension. The most common symptom was cough in 58 patients (70%). The overall mortality was 15%, and 85% of the patients were discharged. The time between the onset of symptoms and hospitalization was statistically significantly longer in deceased patients (P = 0.039). Age, D-Dimer, troponin, CK, CK-MB, ferritin, procalcitonin, and neutrophil to lymphocyte ratio were statistically significantly higher in deceased patients than survivor patients. In subgroup analysis, in the patients receiving azithromycin plus hydroxychloroquine and other antibiotics plus hydroxychloroquine, the duration of hospitalization was shorter in the azithromycin group (P = 0.027). Conclusion: Early treatment and early admission to the hospital can be crucial for the better treatment process. Combination therapy with azithromycin may be preferred in the first treatment choice because it can shorten the length of hospital stay. This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors: Yuwei Liu; Xuebei Du; Jing Chen; Yalei Jin; Li Peng; Harry H X Wang; Mingqi Luo; Ling Chen; Yan Zhao Journal: J Infect Date: 2020-04-10 Impact factor: 6.072
Authors: Philippe Gautret; Jean-Christophe Lagier; Philippe Parola; Van Thuan Hoang; Line Meddeb; Jacques Sevestre; Morgane Mailhe; Barbara Doudier; Camille Aubry; Sophie Amrane; Piseth Seng; Marie Hocquart; Carole Eldin; Julie Finance; Vera Esteves Vieira; Hervé Tissot Tissot-Dupont; Stéphane Honoré; Andreas Stein; Matthieu Million; Philippe Colson; Bernard La Scola; Véronique Veit; Alexis Jacquier; Jean-Claude Deharo; Michel Drancourt; Pierre Edouard Fournier; Jean-Marc Rolain; Philippe Brouqui; Didier Raoult Journal: Travel Med Infect Dis Date: 2020-04-11 Impact factor: 6.211
Authors: Eu Suk Kim; Bum Sik Chin; Chang Kyung Kang; Nam Joong Kim; Yu Min Kang; Jae Phil Choi; Dong Hyun Oh; Jeong Han Kim; Boram Koh; Seong Eun Kim; Na Ra Yun; Jae Hoon Lee; Jin Yong Kim; Yeonjae Kim; Ji Hwan Bang; Kyoung Ho Song; Hong Bin Kim; Ki Hyun Chung; Myoung Don Oh Journal: J Korean Med Sci Date: 2020-04-06 Impact factor: 2.153
Authors: J M Molina; C Delaugerre; J Le Goff; B Mela-Lima; D Ponscarme; L Goldwirt; N de Castro Journal: Med Mal Infect Date: 2020-03-30 Impact factor: 2.152